

# HPV Vaccines

## Issues for ACIP Consideration

Advisory Committee on Immunization Practices  
February 27, 2008

Lauri Markowitz, MD  
NCHHSTP/CDC



DEPARTMENT OF HEALTH AND HUMAN SERVICES  
CENTERS FOR DISEASE CONTROL AND PREVENTION



# Projected Dates for ACIP Vote

| Possible Dates | Vote                                      | Dissemination      |
|----------------|---|--------------------|
| Feb 2008       | -   | -                  |
| June/Oct 2008  | Quadrivalent vaccine<br>females 27-45 yrs | Notice to Readers  |
| 2008 - 2009    | Bivalent vaccine<br>females               | New ACIP Statement |
| 2009           | Quadrivalent vaccine<br>males             | Notice to Readers  |

# Quadrivalent HPV vaccine in women 27-45 years of age

---

- High efficacy for prevention of HPV 6,11,16,18 related CIN or EGL among those naive to the respective HPV vaccine type
- Generally well tolerated

# Key Points

---

- HPV acquisition occurs soon after sexual debut
- HPV prevalence highest in 20-24 yr olds
- Infections occur in females >26 yrs, but incidence decreases with increasing age
- Questions remain about some aspects of HPV natural history
- HPV vaccine is prophylactic; vaccine will have greatest impact and is most cost effective when administered before exposure to HPV
- Models show cost effectiveness of vaccination decreases with increasing age
  - Age at which vaccine not 'cost effective' differs by model

# Quadrivalent HPV Vaccine Recommendations in the US

---

- Routine vaccination of females  
11-12 years
- Catch-up vaccination of females  
13-26 years

# Quadrivalent HPV vaccine

## Recommendation Options for Older Women (27-45 years)

---

- Not recommended
- Permissive recommendation
- Targeted catch-up recommendation
  - Risk-based
- Extend catch-up recommendation
  - all or part of this age group

# Quadrivalent HPV vaccine Recommendations

## Options for Older women (27-45 yrs)

---

### **Option: Not recommended**

#### Rationale

- Likelihood of prior infection higher and incidence lower in this age group
- Less cost effective
- There is secondary prevention for cervical cancer

#### Concerns

- Various

# Quadrivalent HPV vaccine Recommendations Options for Older women (27-45 yrs)

---

## **Option: Permissive Recommendation**

### Rationale

- Some individuals could benefit from vaccination

### Concerns

- Insurance may not cover; some women who could benefit would not be vaccinated
- Vaccine use in persons for whom there is little/no benefit

# Quadrivalent HPV vaccine Recommendations Options for Older women (27-45 yrs)

---

## **Option: Targeted catch-up recommendation (Risk-based)**

### Rationale

- Some individuals could benefit from vaccination

### Concerns

- Risk factors for prevalent infection and past exposure are similar to those associated with incident infection
- Difficult to use sexual behavior criteria
- No clinically available tests to identify who has been infected or is immune to a specific HPV type

# Quadrivalent HPV vaccine Recommendations Options for Older Women (27-45 years)

---

## **Option: Extend catch-up recommendation in all or part of this age group**

### Rationale

- Some women could benefit from vaccine; difficult to target
- Could allow easier access to vaccine than permissive

### Concerns

- Likelihood of prior infection higher and incidence lower
- Vaccine use in persons for whom there is little/no benefit
- Could discourage Pap testing
- Cost/QALY may be very high in all or part of this age group

# Quadrivalent HPV vaccine

## Recommendations Options Being Considered by Workgroup

---

- Not recommended
- Permissive recommendation
- Extend catch-up recommendation
  - all or part of this age group

# ACIP HPV Vaccine WG Plans

---

- Develop recommendation options for women 27-45 years
  - Preparation for possible vote in June/Oct 2008
- Continue to prepare recommendations for bivalent vaccine
- Prepare for consideration of vaccine recommendations for males